Transmetalation in Cancer Pharmacology
International Journal of Molecular Sciences · 14.11.2025 · 26 (22) · 11008
DOI: 10.3390/ijms262211008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.11.2025. Verfasst von Mahendiran Dharmasivam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4215, Australia. Hauptthemen laut MEDLINE: Neoplasms, Coordination Complexes, Antineoplastic Agents, Metals. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, NHMRC MRFF, Thrasher Research Fund.
Abstract (Originalsprache)
Transmetalation, the exchange of metal ions between coordination complexes and biomolecules, has emerged as a powerful design lever in cancer metallopharmacology. Using thiosemicarbazones (TSCs) as a unifying case study, we show how redox-inert carrier states such as zinc(II) or gallium(III) can convert in situ into redox-active copper(II) or iron(III/II) complexes within acidic, metal-rich lysosomes. This conditional activation localizes reactive oxygen species (ROS) generation and iron deprivation to tumor cells. We critically compare redox-active and redox-inert states, delineating how steric and electronic tuning, backbone rigidity, and sulfur-to-selenium substitution govern exchange hierarchies and kinetics. We further map downstream consequences for metal trafficking, lysosomal membrane permeabilization, apoptosis, and ferroptosis. Beyond TSCs, iron(III)-targeted transmetalation from titanium(IV)-chelator “chemical transferrin mimetics” illustrates a generalizable Trojan horse paradigm. We conclude with translational lessons, including mitigation of hemoprotein oxidation via steric shielding, stealth zinc(II) prodrugs, and dual-chelator architectures and outline biomarker, formulation, and imaging strategies that de-risk clinical development. Collectively, these insights establish transmetalation as a central therapeutic principle. We also highlight open challenges such as quantifying in-cell exchange kinetics, predicting speciation under non-equilibrium conditions, and rationally combining these agents with existing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4215, Australia.
ORCID-Profile: Mahendiran Dharmasivam, Busra Kaya
Förderung
- National Health and Medical Research Council
- NHMRC MRFF
- Thrasher Research Fund
Zitieren
APA
Dharmasivam, M., & Kaya, B. (2025). Transmetalation in Cancer Pharmacology. International Journal of Molecular Sciences, 26(22), 11008. https://doi.org/10.3390/ijms262211008
Vancouver
Dharmasivam M, Kaya B. Transmetalation in Cancer Pharmacology. International Journal of Molecular Sciences. 2025;26(22):11008. doi:10.3390/ijms262211008
BibTeX
@article{Dharmasivam2025,
author = {Dharmasivam, Mahendiran and Kaya, Busra},
title = {Transmetalation in Cancer Pharmacology},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {22},
pages = {11008},
doi = {10.3390/ijms262211008}
}
EUVIMED